Reem Karmali

51PUBLICATIONS
233CO-AUTHORS
Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)AutoimmunityMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (51)

|Aug 20, 2026
Second Line CD19 CAR-T vs Platinum Salvage and Autologous Stem Cell Transplant for Primary Mediastinal B-Cell Lymphoma.

|Apr 25, 2026
Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton's tyrosine kinase inhibitor therapy.

|Apr 17, 2026
A Phase 2, Open-Label, Multicenter Study of the Safety and Efficacy of TAK-007 in Adult Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma.

|Dec 11, 2025
Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma.

Yucai Wang, Melissa C Larson, Steven R Hwang

|Nov 07, 2025
Outcomes for CART as 2L vs 3L vs 4L or beyond in aggressive B-cell lymphoma: real-world evidence from the ABC Consortium.

John S Wang, Brandon L Ellsworth, Megan Melody

|Aug 05, 2025
Treatment and outcomes of progression of disease post-CAR T-cell therapy in mantle cell lymphoma: a multicenter analysis.

Zachary D Epstein-Peterson, Anath C Lionel, Ashlee Joseph

Pageof 9

Frequent Collaborators

21 joint publications

Narendranath Epperla

16 joint publications

Leo I Gordon

14 joint publications

Jonathon Cohen

13 joint publications

Natalie Sophia Grover